Medical School · Year 3 · General Surgery · includes a quiz and discussion video

Seminar 18: Surgical Oncology Principles

General Surgery Clerkship - Unit 18

Learning Objectives

By the end of this seminar, students will be able to:

1. Apply the TNM staging system to classify malignancies and predict prognosis across major tumor types
2. Describe surgical oncology principles including intent of surgery, margin assessment, and resection techniques
3. Integrate multimodal therapy concepts including neoadjuvant and adjuvant treatment strategies
4. Apply sentinel lymph node biopsy principles and interpret results to guide surgical management
5. Evaluate and manage cutaneous melanoma from diagnosis through treatment and surveillance
6. Recognize soft tissue sarcoma presentation, complete appropriate workup, and apply treatment principles

Seminar Outline

I. Cancer Staging Principles and the TNM System

The TNM staging system provides a standardized framework for classifying malignant tumors based on anatomic extent of disease. Developed and maintained by the American Joint Committee on Cancer (AJCC), this system enables consistent communication among clinicians, guides treatment decisions, and facilitates comparison of outcomes across institutions and clinical trials. The fundamental components assess three anatomic features: the primary tumor (T), regional lymph nodes (N), and distant metastases (M). Each cancer type has specific criteria within this framework, reflecting the natural history and prognostic factors unique to that malignancy. Staging may be clinical, based on physical examination and imaging, or pathologic, incorporating findings from surgical resection and histopathologic examination.

The T category describes the size and local extent of the primary tumor. T0 indicates no evidence of primary tumor, while Tis represents carcinoma in situ with malignant cells confined to the epithelium without invasion through the basement membrane. T1 through T4 designations indicate progressively larger or more locally invasive tumors, with specific size or depth cutoffs varying by cancer type. For example, breast cancer uses tumor diameter, while colon cancer uses depth of bowel wall invasion. The T stage influences treatment planning by determining feasibility of surgical resection, need for neoadjuvant therapy to reduce tumor burden, and requirement for adjuvant treatment to address local recurrence risk.

The N category indicates the presence and extent of regional lymph node involvement. N0 signifies no regional node metastases, confirmed either clinically or pathologically. Higher N categories (N1, N2, N3) reflect increasing nodal burden, whether measured by number of involved nodes, nodal station location, or presence of extracapsular extension. Lymph node status frequently represents the most important prognostic factor for solid tumors, as nodal metastases indicate capacity for systemic spread. The nodal basins assessed depend on the primary tumor site and known lymphatic drainage patterns. Pathologic nodal staging requires adequate lymph node sampling, with minimum node counts specified for common cancer types.

The M category designates presence or absence of distant metastatic disease. M0 indicates no distant metastases, while M1 confirms metastatic spread to distant organs or non-regional lymph nodes. The M category generally has the greatest impact on prognosis, as distant metastases typically preclude curative surgical resection. Some staging systems subdivide M1 based on location or extent of metastatic disease, as outcomes may vary by metastatic site. Oligometastatic disease, a recently recognized state with limited metastatic burden, may be amenable to local treatment of metastases combined with systemic therapy. Overall stage groupings (0, I, II, III, IV) combine TNM categories to predict survival and guide treatment intensity.

<image>Panel A: TNM staging diagram showing T categories with increasing tumor size and local invasion, N categories depicting escalating lymph node involvement from N0 to N3, and M0 versus M1 designating absence or presence of distant metastases. Panel B: Stage grouping matrix demonstrating how T, N, and M categories combine into overall stage 0 through IV, with representative 5-year survival percentages for each stage. Panel C: Cancer-specific staging examples comparing breast (tumor size-based T staging) with colon (depth of invasion-based T staging) to illustrate variation in criteria. Panel D: Clinical versus pathologic staging comparison showing how imaging-based staging may be revised after surgical resection and pathologic examination.</image>

II. Surgical Oncology Principles and Terminology

The intent of surgical intervention in oncology fundamentally shapes operative planning and patient counseling. Curative surgery aims for complete tumor removal with the goal of eliminating all detectable disease and achieving long-term survival or cure. This typically requires R0 resection, defined as microscopically negative surgical margins with no residual tumor remaining. Palliative surgery relieves symptoms or prevents complications without intent to cure, employed when complete resection is not possible or when metastatic disease precludes cure. Debulking or cytoreductive surgery maximally reduces tumor burden before chemotherapy, improving drug delivery and effectiveness, as employed in ovarian cancer. Prophylactic surgery removes at-risk organs before cancer develops in individuals with hereditary cancer syndromes.

Surgical margin assessment determines completeness of resection and predicts local recurrence risk. R0 resection indicates microscopically negative margins, representing the optimal oncologic outcome. R1 resection has microscopically positive margins, where tumor extends to the inked surgical margin on pathologic examination, indicating increased local recurrence risk. R2 resection leaves grossly visible tumor, representing incomplete resection with high likelihood of local progression. Margin width requirements vary by cancer type: melanoma requires 1-2 cm margins depending on depth, while breast cancer requires no ink on tumor for most lumpectomy specimens. Close margins, while technically negative, may prompt consideration of re-excision or adjuvant radiation depending on clinical context.

Resection types reflect the extent of tissue removal required for oncologic adequacy. Simple excision removes the lesion with minimal surrounding tissue, appropriate for benign lesions or very superficial malignancies. Wide local excision removes the tumor with a circumferential margin of normal tissue, the standard approach for solid tumor resection. Radical resection involves en bloc removal of the tumor along with contiguous structures at risk for direct invasion, including adjacent organs, fascia, or soft tissue. Compartmental resection removes an entire anatomic compartment when the tumor involves the full compartment. Multivisceral resection addresses locally advanced tumors involving multiple organs, removing all involved structures together to avoid tumor violation.

Lymph node surgery has evolved toward more selective approaches that minimize morbidity while maintaining oncologic adequacy. Sentinel lymph node biopsy identifies and examines the first lymph node or nodes receiving drainage from the tumor, allowing accurate staging without complete nodal dissection. If the sentinel node is negative, the remaining nodal basin can be spared the morbidity of complete dissection. Completion lymph node dissection removes all nodes in a regional basin following positive sentinel node, though recent trials challenge its necessity in select situations. Therapeutic lymphadenectomy addresses clinically apparent nodal disease detected before surgery. Elective lymph node dissection, once routinely performed, has largely been replaced by sentinel node biopsy for staging clinically negative nodes.

<image>Panel A: Surgical intent categories illustrated with curative resection achieving R0 margins, palliative surgery relieving obstruction from unresectable tumor, and prophylactic surgery removing at-risk organs. Panel B: Margin status classification showing R0 (clear margins with distance from tumor to edge), R1 (microscopic tumor at margin), and R2 (gross residual tumor) with pathology correlation. Panel C: Resection extent spectrum from simple excision through wide local excision to radical en bloc resection with contiguous structures. Panel D: Lymph node surgery options comparing sentinel node biopsy, completion dissection, and therapeutic lymphadenectomy with morbidity considerations.</image>

III. Multimodal Therapy: Neoadjuvant and Adjuvant Approaches

Neoadjuvant therapy refers to systemic treatment or radiation administered before surgical resection. The primary goals include tumor downsizing to convert unresectable tumors to resectable, reduction in surgical extent to enable organ-sparing or less morbid procedures, and early treatment of micrometastatic disease. Neoadjuvant therapy also provides in vivo assessment of tumor response, where pathologic complete response (pCR) indicates favorable biology and improved prognosis. Common applications include chemoradiation for locally advanced rectal cancer, chemotherapy for inflammatory or large breast cancers, and chemoradiation for esophageal cancer. Neoadjuvant therapy may delay definitive surgical treatment, creating concern about disease progression in non-responders, though careful selection and monitoring minimize this risk.

Adjuvant therapy follows surgical resection with the goal of eradicating residual micrometastatic disease not removed at surgery. Even with R0 resection, microscopic disease may persist locally or systemically, manifesting as recurrence months to years later. Adjuvant treatment decisions balance the risk of recurrence, magnitude of treatment benefit, and treatment toxicity. Stage-specific recommendations derive from randomized trials demonstrating improved disease-free and overall survival. Common adjuvant regimens include chemotherapy for stage III colon cancer, endocrine therapy and chemotherapy for hormone receptor-positive breast cancer, and radiation for high-grade soft tissue sarcoma. Timing typically falls within 4-8 weeks of surgery, once the patient has recovered from the operative procedure.

Systemic therapy options have expanded dramatically beyond traditional cytotoxic chemotherapy. Chemotherapy agents disrupt cell division through various mechanisms including DNA damage, antimetabolite activity, and mitotic inhibition, affecting all rapidly dividing cells including normal tissues. Targeted therapies exploit specific molecular vulnerabilities in cancer cells, such as HER2-directed therapy in breast cancer or BRAF inhibitors in melanoma, providing greater selectivity and often different toxicity profiles. Immunotherapy harnesses the patient's immune system to recognize and attack cancer cells, with checkpoint inhibitors blocking PD-1, PD-L1, or CTLA-4 pathways that tumors exploit to evade immune surveillance. Hormone therapy blocks hormone signaling in cancers dependent on estrogen, progesterone, or androgen receptor activation.

Radiation therapy uses ionizing radiation to damage tumor cell DNA and prevent proliferation. External beam radiation delivers targeted doses to the tumor bed from outside the body, with intensity-modulated techniques sparing normal tissues. Brachytherapy places radioactive sources directly within or adjacent to the tumor, providing high local doses with rapid fall-off to protect surrounding structures. Neoadjuvant radiation downstages locally advanced tumors, particularly effective combined with chemotherapy for rectal and esophageal cancers. Adjuvant radiation improves local control after surgical resection, especially for positive or close margins. Definitive radiation serves as primary treatment for tumors where surgery would cause unacceptable morbidity, such as laryngeal cancer where preservation of voice function is desired.

<image>Panel A: Neoadjuvant therapy schema showing tumor downsizing sequence with imaging-based response assessment, surgical resection, and pathologic response evaluation demonstrating complete response versus residual disease. Panel B: Adjuvant therapy decision algorithm incorporating stage, molecular markers, and recurrence risk to select chemotherapy, radiation, targeted therapy, or observation. Panel C: Systemic therapy mechanism comparison showing cytotoxic chemotherapy affecting dividing cells, targeted therapy blocking specific pathways, and checkpoint inhibitor immunotherapy releasing immune brakes. Panel D: Radiation therapy modalities comparing external beam techniques with intensity modulation, brachytherapy with local source placement, and treatment planning images showing dose distribution.</image>

IV. Sentinel Lymph Node Biopsy Principles

The sentinel lymph node concept rests on the observation that tumors drain through lymphatic channels to predictable regional nodes in an orderly fashion. The sentinel node, or nodes, represents the first lymphatic station receiving drainage from the primary tumor site. The principle holds that if the sentinel node is negative for metastatic disease, the remaining nodes in that basin have a very low probability of harboring metastases, making complete nodal dissection unnecessary. Conversely, a positive sentinel node indicates nodal basin involvement requiring further treatment, either complete dissection or systemic therapy. Sentinel lymph node biopsy has replaced routine elective lymph node dissection for staging clinically node-negative patients across multiple cancer types, substantially reducing the morbidity of lymphedema, nerve injury, and seroma formation.

The technical approach employs radiotracer, blue dye, or both to identify the sentinel node or nodes. Technetium-99m labeled sulfur colloid or tilmanocept is injected around the tumor or biopsy site hours before surgery, traveling through lymphatics to accumulate in sentinel nodes. Intraoperatively, a handheld gamma probe detects the radioactive signal, guiding the surgeon to the sentinel node. Isosulfan blue or methylene blue dye injected at the start of surgery visually stains the lymphatic channels and sentinel nodes, providing a complementary identification method. The dual technique using both radiotracer and blue dye achieves identification rates exceeding 95% and false-negative rates below 5%. Emerging technologies including indocyanine green fluorescence imaging and superparamagnetic iron oxide particles offer alternatives with potential advantages.

Sentinel lymph node biopsy has become standard of care for breast cancer and melanoma staging. In breast cancer, SLNB is indicated for invasive carcinoma with clinically negative axilla, determining the need for axillary dissection and influencing systemic therapy recommendations. The Z0011 trial demonstrated that patients with limited sentinel node metastases undergoing lumpectomy with radiation may safely omit axillary dissection. In melanoma, SLNB is recommended for tumors greater than 0.8 mm Breslow thickness or with ulceration, providing important prognostic information and guiding adjuvant therapy decisions. Additional applications include vulvar cancer, penile cancer, and select gastrointestinal malignancies. Head and neck mucosal cancers present anatomic challenges but SLNB is increasingly utilized for oral cavity tumors.

Management of positive sentinel nodes has evolved with recent trial evidence. In melanoma, the DeCOG-SLT and MSLT-II trials demonstrated that immediate completion lymph node dissection does not improve melanoma-specific survival compared with nodal observation using ultrasound, though dissection does improve nodal basin control. For breast cancer, the Z0011 and AMAROS trials established that not all positive sentinel nodes require axillary dissection, with radiation or observation appropriate in selected patients undergoing breast-conserving therapy. The number and extent of nodal metastases, planned treatments including radiation, and extranodal extension influence decisions. Multidisciplinary tumor board discussion integrates pathologic findings with patient factors and treatment plans to determine optimal management of positive sentinel nodes.

<image>Panel A: Sentinel lymph node concept illustration showing primary tumor with lymphatic drainage to sentinel node before spread to secondary nodes, demonstrating the orderly progression principle underlying SLNB. Panel B: SLNB technique showing radiotracer injection and lymphoscintigraphy image, intraoperative gamma probe detection, and blue dye visual identification with stained lymphatic channels. Panel C: SLNB decision algorithm for breast cancer and melanoma showing thickness/ulceration criteria, procedure steps, and management pathways based on pathologic results. Panel D: Positive sentinel node management options comparing completion lymph node dissection, nodal observation with imaging surveillance, and radiation as alternative approaches with supporting trial evidence.</image>

V. Melanoma: Epidemiology, Diagnosis, and Primary Treatment

Melanoma arises from malignant transformation of melanocytes, the pigment-producing cells derived from neural crest. Incidence has increased dramatically over recent decades, now representing the fifth most common cancer in the United States with over 100,000 new cases annually. The primary modifiable risk factor is ultraviolet radiation exposure, including both sunlight and artificial tanning devices, with intermittent intense exposure and blistering sunburns particularly associated with risk. Constitutional factors include fair skin, light hair and eye color, tendency to burn rather than tan, and presence of numerous or atypical nevi. Approximately 10% of melanomas occur in familial clusters, with germline mutations in CDKN2A and other genes conferring substantially elevated risk. The four major histologic subtypes include superficial spreading (most common), nodular (most aggressive), lentigo maligna (occurring on sun-damaged skin), and acral lentiginous (occurring on palms, soles, and nail beds).

Clinical recognition employs the ABCDE criteria to identify suspicious pigmented lesions. Asymmetry indicates irregular shape where one half does not match the other. Border irregularity manifests as notched, scalloped, or poorly defined margins rather than smooth, round borders. Color variation includes multiple shades of brown, black, red, white, or blue within the same lesion. Diameter greater than 6 mm, roughly the size of a pencil eraser, raises concern, though smaller melanomas can occur. Evolution describes change in size, shape, color, or symptoms such as bleeding, itching, or ulceration, often the most sensitive criterion for identifying early melanoma. The "ugly duckling" sign identifies a lesion that looks different from the patient's other nevi. Any concerning lesion requires biopsy, preferably excisional with narrow margins to allow complete pathologic assessment.

Breslow depth, measuring tumor thickness from the granular layer of the epidermis to the deepest point of invasion, represents the most important prognostic factor for localized melanoma. Tumors 1.0 mm or less (T1) carry 5-year survival exceeding 95%, while tumors greater than 4.0 mm (T4) have survival of approximately 50%. Ulceration of the primary tumor, identified histologically as absence of intact epidermis overlying the melanoma, is an independent adverse prognostic factor that upstages the T category. Mitotic rate, measuring proliferative activity, provides additional prognostic information. Satellite lesions, in-transit metastases, and microsatellites indicate locally advanced disease with worse prognosis. Molecular features including BRAF mutation status (present in approximately 50% of cutaneous melanomas) have treatment implications for advanced disease.

Surgical treatment of the primary melanoma requires wide local excision with margins determined by Breslow depth. Melanoma in situ requires 0.5-1.0 cm margins. Tumors 1.0 mm or less require 1 cm margins, while tumors 1.01-2.0 mm require 1-2 cm margins. Tumors greater than 2.0 mm require 2 cm margins. Margins extend to but not including underlying fascia in most cases. Reconstruction may require skin grafting or flap closure for larger defects, particularly in cosmetically or functionally sensitive areas. Sentinel lymph node biopsy is indicated for tumors greater than 0.8 mm Breslow depth, for thinner melanomas with ulceration, or when other high-risk features are present. The primary excision and sentinel node biopsy are typically performed simultaneously, with definitive wide excision completing treatment once final pathology is available.

<image>Panel A: Melanoma risk factors and epidemiology showing ultraviolet exposure effects, Fitzpatrick skin types with risk stratification, and familial melanoma genetics with CDKN2A pathway. Panel B: ABCDE criteria photographs demonstrating Asymmetry, Border irregularity, Color variation, Diameter larger than 6mm, and Evolution with before/after images showing change over time. Panel C: Breslow depth measurement illustration showing progressively deeper invasion from in situ through T1-T4 categories with corresponding survival curves. Panel D: Wide local excision margins table by Breslow depth with surgical planning photographs showing margin marking and closure options.</image>

VI. Advanced and Metastatic Melanoma

Lymph node management depends on clinical and pathologic staging. Patients with clinically negative nodes and positive sentinel node biopsy face decisions regarding completion lymph node dissection versus observation with imaging surveillance. The MSLT-II and DeCOG-SLT trials demonstrated equivalent melanoma-specific survival between immediate dissection and nodal surveillance, though dissection provides better regional control. Factors favoring completion dissection include high sentinel node tumor burden, extracapsular extension, and patient preference. Observation protocols involve clinical examination and nodal basin ultrasound every 4 months initially. Patients with clinically apparent nodal disease at presentation undergo therapeutic lymphadenectomy with adjuvant therapy, typically achieving regional control while addressing systemic disease risk.

Adjuvant systemic therapy has transformed outcomes for high-risk resected melanoma. Patients with stage IIB, IIC, or III melanoma after complete resection benefit from adjuvant immunotherapy with anti-PD-1 checkpoint inhibitors (nivolumab or pembrolizumab), reducing recurrence risk by approximately 40-50%. Treatment duration is typically one year, with side effects including immune-mediated toxicities affecting multiple organ systems. For patients with BRAF-mutant melanoma, adjuvant BRAF/MEK inhibitor combination (dabrafenib/trametinib) provides an alternative with different toxicity profile. Selection between immunotherapy and targeted therapy considers mutation status, patient comorbidities, and preference regarding toxicity profiles. Adjuvant radiation may be considered for resected nodal disease with high-risk features including extracapsular extension or multiple involved nodes.

Metastatic melanoma treatment has achieved remarkable advances through immunotherapy and targeted therapy. First-line treatment for unresectable or metastatic disease typically involves anti-PD-1 therapy alone or combined with anti-CTLA-4 (ipilimumab), achieving response rates of 40-60% with durable responses in many patients. Combined checkpoint blockade offers higher response rates but increased toxicity. For BRAF-mutant melanoma (V600E or V600K mutations), BRAF/MEK inhibitor combinations provide rapid response rates exceeding 60%, though resistance typically develops within 12-18 months. Sequencing of immunotherapy and targeted therapy in BRAF-mutant patients remains an area of investigation. Oligometastatic disease may be addressed with surgical resection or stereotactic radiation combined with systemic therapy.

Surveillance after melanoma treatment monitors for local recurrence, regional nodal recurrence, and distant metastases. For stage I-II melanoma, surveillance involves comprehensive skin examination and regional node palpation every 3-12 months for 5-10 years, with frequency determined by stage and risk factors. For stage III-IV resected melanoma, more intensive surveillance includes physical examination and cross-sectional imaging (CT chest/abdomen/pelvis) every 3-6 months for 2 years, then every 6-12 months through year 5. Brain MRI is considered for high-risk patients given melanoma's propensity for CNS metastases. Patient education regarding self-examination, sun protection, and recognition of new concerning lesions enables early detection of recurrence or second primary melanomas, which occur in 5-10% of melanoma survivors.

<image>Panel A: Lymph node management decision tree showing pathways from positive sentinel node through completion dissection versus observation, with imaging surveillance protocol and triggers for intervention. Panel B: Adjuvant therapy options for resected high-risk melanoma comparing anti-PD-1 immunotherapy with BRAF/MEK targeted therapy, showing efficacy data, duration, and toxicity profiles. Panel C: Metastatic melanoma treatment algorithm showing first-line options, BRAF mutation testing workflow, response assessment, and subsequent line therapies. Panel D: Surveillance schedule by melanoma stage showing examination intervals, imaging modalities, and duration of follow-up with recurrence patterns by site.</image>

VII. Soft Tissue Sarcoma: Epidemiology and Presentation

Soft tissue sarcomas comprise a heterogeneous group of mesenchymal malignancies arising from connective tissues including muscle, fat, blood vessels, nerves, and fibrous tissue. These tumors are rare, accounting for less than 1% of adult malignancies with approximately 13,000 new cases annually in the United States. Over 50 histologic subtypes exist, each with distinct molecular features, clinical behavior, and treatment response. The most common subtypes include liposarcoma, leiomyosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor. Anatomic distribution favors the extremities (approximately 60%), particularly the thigh, followed by the retroperitoneum (approximately 20%), with the remainder arising in the trunk wall, head and neck, and visceral organs. Unlike carcinomas, most sarcomas arise sporadically without identifiable risk factors, though radiation exposure, chronic lymphedema, and certain genetic syndromes increase risk.

Clinical presentation typically involves a painless enlarging mass that may have been present for weeks to months before medical evaluation. Extremity sarcomas often grow to substantial size before causing symptoms, as deep location within muscle compartments accommodates expansion. Pain occurs when tumors compress adjacent nerves or involve bone. Rapid growth over weeks suggests aggressive behavior and warrants urgent evaluation. Constitutional symptoms including weight loss and fever are uncommon except in advanced disease. Retroperitoneal sarcomas may reach massive size before detection, causing vague abdominal discomfort, early satiety, or lower extremity edema from vascular compression. The clinical "rule of twos" suggests that masses larger than 2 cm, deeper than 2 cm from the skin, or growing for more than 2 weeks warrant investigation.

Physical examination should characterize mass size, location relative to fascia (superficial or deep), fixation to surrounding structures, and relationship to neurovascular structures. Deep location and size greater than 5 cm are concerning features that increase sarcoma probability. Superficial lipomas, the most common soft tissue tumors, are soft, mobile, and have characteristic consistency, though atypical features warrant imaging. Examination of the regional lymph node basin is performed, though sarcomas rarely metastasize to lymph nodes (exception: epithelioid sarcoma, clear cell sarcoma, angiosarcoma). Neurologic examination assesses for nerve involvement. The contralateral extremity provides comparison for symmetric masses that may represent normal anatomic variants or benign conditions.

Diagnostic evaluation begins with imaging before any tissue sampling. MRI with gadolinium contrast is the imaging modality of choice for extremity masses, providing excellent soft tissue characterization, tumor extent delineation, and relationship to neurovascular structures. CT imaging is preferred for retroperitoneal tumors and provides chest staging for pulmonary metastases. PET imaging may assist in grading (higher-grade tumors typically show increased uptake) and staging but is not routinely required. Core needle biopsy, rather than incisional biopsy, is the preferred tissue diagnosis approach, providing adequate tissue for histologic subtyping, grading, and molecular studies while minimizing contamination of tissue planes. The biopsy tract must be placed to allow excision en bloc with the definitive resection specimen. Excisional biopsy without prior imaging or planning risks incomplete resection and compromised subsequent treatment.

<image>Panel A: Soft tissue sarcoma epidemiology showing anatomic distribution (extremity, retroperitoneum, trunk), common histologic subtypes with relative frequencies, and age distribution patterns. Panel B: Clinical presentation features illustrating deep location within muscle compartment, rapid growth pattern, and relationship to surrounding structures with concerning features for malignancy. Panel C: Physical examination technique showing size measurement, depth assessment relative to fascia, mobility testing, and neurovascular evaluation. Panel D: Imaging evaluation comparing MRI of extremity sarcoma with soft tissue characterization and neurovascular relationship to CT of retroperitoneal sarcoma showing displacement of adjacent organs.</image>

VIII. Soft Tissue Sarcoma: Grading and Treatment

Sarcoma grading is the most important prognostic factor, predicting both local recurrence and metastatic potential. The French Federation of Cancer Centers Sarcoma Group (FNCLCC) grading system is most widely used, incorporating three histologic parameters. Tumor differentiation (1-3 points) assesses how closely the tumor resembles normal tissue of origin, with well-differentiated tumors scoring lower. Mitotic count (1-3 points) measures proliferative activity by counting mitoses per 10 high-power fields. Tumor necrosis (0-2 points) reflects the presence and extent of spontaneous necrosis. Total scores of 2-3 points indicate grade 1 (low grade), 4-5 points grade 2 (intermediate), and 6-8 points grade 3 (high grade). High-grade tumors have substantially higher rates of metastasis and death, while low-grade tumors have excellent prognosis with appropriate local treatment. Grading influences decisions regarding adjuvant therapy and surveillance intensity.

Surgical resection with wide local excision remains the primary treatment for localized soft tissue sarcoma. Adequate margins typically require 1-2 cm of normal tissue or an intact fascial plane surrounding the tumor. The goal is R0 resection with microscopically negative margins while preserving limb function. Limb-sparing surgery has become standard of care, with amputation reserved for tumors that cannot be resected with adequate margins while preserving a functional limb. Advances in reconstructive surgery, including free tissue transfer, expand options for coverage and functional restoration after wide resection. Retroperitoneal sarcomas require en bloc resection with involved adjacent organs, as marginal excision along the tumor capsule leads to unacceptable local recurrence rates. Multivisceral resection, often including kidney, colon, and psoas muscle, is frequently necessary.

Radiation therapy improves local control for intermediate and high-grade soft tissue sarcomas. Preoperative radiation, typically 50 Gy over 5 weeks, is preferred for most extremity sarcomas, allowing smaller radiation fields and potentially facilitating resection. Wound healing complications are more common with preoperative radiation but can be managed with delayed surgery and careful wound care. Postoperative radiation requires higher doses (60-66 Gy) and larger fields but avoids wound complications. Radiation reduces local recurrence from approximately 25-30% to 5-10% for high-grade tumors. Retroperitoneal sarcomas present challenges for radiation given adjacent bowel sensitivity, though radiation may be considered in select cases. Brachytherapy, placing radioactive catheters in the tumor bed at resection, provides an alternative delivery method.

Chemotherapy has a more limited role in soft tissue sarcoma than in many carcinomas. Neoadjuvant chemotherapy may be considered for large, high-grade extremity sarcomas, potentially improving resectability and providing early systemic treatment. Adjuvant chemotherapy is not routinely recommended, as meta-analyses show only modest survival benefit with significant toxicity. Histology-specific approaches recognize that certain subtypes respond better to chemotherapy, including synovial sarcoma, myxoid liposarcoma, and pediatric sarcomas. First-line agents include doxorubicin and ifosfamide, with response rates of 20-30%. Newer targeted agents, including pazopanib for non-adipocytic sarcomas and trabectedin for liposarcoma and leiomyosarcoma, provide additional options for advanced disease. Surveillance after treatment involves clinical examination and imaging at 3-6 month intervals, continuing for 10 years given the potential for late recurrence.

<image>Panel A: FNCLCC grading system components showing differentiation scoring criteria, mitotic count thresholds, and necrosis percentage assessment with total score calculation and grade assignment. Panel B: Surgical resection principles illustrating wide local excision with 1-2 cm margins or fascial plane, limb-sparing approach preserving functional structures, and reconstruction options. Panel C: Radiation therapy comparison showing preoperative versus postoperative timing with dose, field size, and wound complication trade-offs for extremity sarcoma treatment. Panel D: Chemotherapy decision algorithm incorporating histologic subtype, tumor grade, size, and patient factors to determine neoadjuvant or adjuvant therapy indications.</image>

IX. Gastrointestinal Stromal Tumors

Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal neoplasm of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors, which function as intestinal pacemaker cells. The molecular hallmark is activating mutation in the KIT receptor tyrosine kinase gene, present in approximately 85% of cases, or PDGFRA (platelet-derived growth factor receptor alpha) mutation in 5-8%. These mutations drive constitutive activation of signaling pathways promoting cell proliferation and survival. GISTs most commonly arise in the stomach (60%) and small intestine (30%), with less frequent occurrence in the esophagus, colon, and rectum. Immunohistochemistry demonstrating CD117 (KIT) positivity confirms the diagnosis, with DOG1 serving as an additional sensitive and specific marker. GIST behavior ranges from benign to highly malignant, necessitating risk stratification to guide treatment.

Risk stratification predicts recurrence following complete resection and guides adjuvant therapy decisions. The most important factors are tumor size, mitotic rate, and anatomic location. Tumors greater than 5 cm and especially greater than 10 cm carry substantially higher recurrence risk. Mitotic rate greater than 5 per 50 high-power fields indicates more aggressive biology. Non-gastric tumors, particularly those arising in the small intestine or rectum, have worse prognosis than gastric GISTs of similar size and mitotic rate. Tumor rupture, whether spontaneous or intraoperative, is associated with very high recurrence risk approaching 100% and mandates adjuvant therapy. The NIH, AFIP, and Joensuu nomograms integrate these factors to calculate recurrence probability and guide treatment recommendations.

Surgical resection is the primary treatment for localized GIST. The goal is complete gross resection with negative margins, achievable through wedge resection for gastric GISTs or segmental resection for intestinal tumors. Wide margins are not required as GISTs spread through hematogenous rather than lymphatic routes; grossly negative margins are adequate. Lymphadenectomy is unnecessary as nodal metastases are rare. Laparoscopic resection is appropriate for favorably located tumors up to approximately 5 cm, avoiding tumor rupture or morcellation. For locally advanced or marginally resectable tumors, neoadjuvant imatinib may reduce tumor size and facilitate less morbid resection. Metastatic disease most commonly involves the liver and peritoneum; metastasectomy may be considered for limited hepatic metastases, particularly in patients with good imatinib response.

Adjuvant imatinib, a selective tyrosine kinase inhibitor targeting KIT and PDGFRA, dramatically improves outcomes for high-risk GIST. The SSGXVIII/AIO trial demonstrated that 3 years of adjuvant imatinib significantly improves recurrence-free and overall survival compared with 1 year for high-risk tumors. Low-risk GISTs (small, low mitotic rate, gastric location) do not require adjuvant therapy given their excellent prognosis with surgery alone. Intermediate-risk tumors may receive 1 year of adjuvant therapy, though the benefit is less certain. Standard dosing is imatinib 400 mg daily, with dose escalation for select mutations. Mutation analysis guides therapy, as PDGFRA D842V mutation confers primary imatinib resistance. For imatinib-resistant or intolerant patients, second-line agents include sunitinib and regorafenib. Indefinite imatinib is recommended for metastatic GIST given high recurrence rates upon discontinuation.

<image>Panel A: GIST molecular pathophysiology diagram showing KIT receptor with activating mutation, downstream signaling pathway activation, and corresponding targeted inhibition by imatinib. Panel B: Risk stratification nomogram incorporating tumor size, mitotic rate, and location with calculated recurrence probability and corresponding treatment recommendations. Panel C: Surgical approaches for GIST showing gastric wedge resection, small bowel segmental resection, and laparoscopic technique with tumor handling precautions to prevent rupture. Panel D: Adjuvant and metastatic therapy algorithm showing imatinib duration by risk category, mutation testing workflow, and second-line options for resistance.</image>

X. Cancer Genetics and Risk-Reducing Surgery

Hereditary cancer syndromes account for 5-10% of all cancers, resulting from germline mutations that substantially increase cancer risk. Hereditary breast and ovarian cancer syndrome (HBOC), caused by BRCA1 or BRCA2 mutations, confers lifetime breast cancer risk of 45-65% and ovarian cancer risk of 10-40%. Lynch syndrome, resulting from mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2), dramatically increases colorectal cancer risk (40-80% lifetime) and endometrial cancer risk (25-60%). Familial adenomatous polyposis (FAP), caused by APC gene mutations, leads to hundreds to thousands of colorectal polyps and virtually 100% lifetime risk of colorectal cancer without prophylactic colectomy. Li-Fraumeni syndrome (TP53 mutations) predisposes to multiple cancer types including sarcoma, breast cancer, brain tumors, and leukemia. Multiple endocrine neoplasia type 2 (RET mutations) causes medullary thyroid carcinoma and pheochromocytoma.

Genetic testing indications include early-onset cancer, multiple primary cancers, family history of multiple affected relatives, and specific histologic features suggesting hereditary etiology. Breast cancer diagnosed before age 50, bilateral breast cancer, male breast cancer, and triple-negative breast cancer warrant BRCA testing consideration. Colorectal cancer before age 50 or with mismatch repair deficiency suggests Lynch syndrome evaluation. Medullary thyroid carcinoma at any age should prompt RET testing. Testing should occur through genetic counseling to ensure informed consent, appropriate test selection, and accurate interpretation. Cascade testing of at-risk relatives follows positive results. Negative testing in an individual without known familial mutation does not exclude hereditary risk; testing the affected relative first is preferred when possible.

Risk-reducing surgery substantially decreases cancer incidence in high-risk individuals. Bilateral prophylactic mastectomy reduces breast cancer risk by approximately 90% in BRCA1/2 mutation carriers, with additional risk-reducing salpingo-oophorectomy addressing ovarian cancer risk and providing further breast cancer risk reduction through hormonal effects. Timing considers reproductive planning and age-related risk curves, with salpingo-oophorectomy typically recommended by age 35-40 for BRCA1 and 40-45 for BRCA2. Prophylactic colectomy is recommended for FAP patients, typically total proctocolectomy with ileal pouch-anal anastomosis or total abdominal colectomy with ileorectal anastomosis depending on rectal polyp burden. For Lynch syndrome, prophylactic hysterectomy with bilateral salpingo-oophorectomy may be considered after childbearing. Prophylactic thyroidectomy in childhood is indicated for RET mutation carriers, with timing based on mutation-specific risk.

Enhanced surveillance provides an alternative or complement to risk-reducing surgery. For BRCA mutation carriers declining or delaying mastectomy, screening includes annual breast MRI and mammography beginning at age 25-30. Lynch syndrome management includes colonoscopy every 1-2 years beginning at age 20-25, with consideration of upper endoscopy for gastric and duodenal cancer screening. FAP surveillance begins with sigmoidoscopy at age 10-12, with annual colonoscopy once polyps develop until colectomy. Surveillance cannot replace risk-reducing surgery for syndromes like FAP where cancer is essentially inevitable. For most hereditary syndromes, multidisciplinary management involving genetic counselors, medical oncologists, and surgeons provides comprehensive care addressing cancer risk, surveillance, prevention options, and psychosocial support for patients and families.

<image>Panel A: Major hereditary cancer syndromes table showing gene, inheritance pattern, associated cancers, and lifetime cancer risks for BRCA1/2, Lynch syndrome, FAP, Li-Fraumeni, and MEN2. Panel B: Genetic testing decision flowchart incorporating personal and family history features, testing strategy, and cascade testing approach for positive results. Panel C: Risk-reducing surgery options by syndrome showing bilateral mastectomy and salpingo-oophorectomy for BRCA, colectomy for FAP, and thyroidectomy for MEN2 with timing recommendations. Panel D: Surveillance protocols by syndrome showing imaging modalities, intervals, and starting ages for screening approaches when surgery is deferred or as complement to surgery.</image>

Summary

• TNM staging classifies tumors by primary tumor extent (T), regional lymph nodes (N), and distant metastases (M), determining prognosis and treatment
• R0 resection indicates microscopically negative margins representing optimal oncologic outcome; R1 has microscopic positive margins; R2 has gross residual tumor
• Neoadjuvant therapy before surgery aims to downsize tumors and treat micrometastases; adjuvant therapy after surgery targets residual microscopic disease
• Sentinel lymph node biopsy identifies the first draining node to stage the nodal basin without complete dissection; negative sentinel node indicates low probability of basin involvement
• Melanoma wide excision margins depend on Breslow depth: in situ 0.5-1 cm, 1 mm or less requires 1 cm, 1.01-2.0 mm requires 1-2 cm, greater than 2.0 mm requires 2 cm
• SLNB is indicated for melanoma greater than 0.8 mm Breslow depth or with ulceration, guiding adjuvant therapy decisions
• Metastatic melanoma treatment uses anti-PD-1 immunotherapy (40-60% response) or BRAF/MEK inhibitors for BRAF-mutant disease (60% response)
• Soft tissue sarcoma treatment is wide local excision with 1-2 cm margins or fascial plane; radiation improves local control for high-grade tumors
• FNCLCC grading (differentiation, mitotic rate, necrosis) is the most important prognostic factor for soft tissue sarcoma
• GIST treatment is surgical resection with adjuvant imatinib for 3 years in high-risk cases; KIT and PDGFRA mutations guide therapy
• Hereditary cancer syndromes (BRCA, Lynch, FAP) warrant genetic testing, risk-reducing surgery consideration, and enhanced surveillance

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown